Our data provide a possible explanation for why SMO inhibitors have not been successful in advanced stage breast cancer patients26, as these patients, particularly if their tumours express EMT-TFs, may activate Hh signalling in a small number of cells, and/or in a SMO-independent manner. The gene discussed is SMO; the disease is breast cancer.